COMMUNIQUÉS West-GlobeNewswire

Nox Peptides Announces Expanded Research Focus on BPC-157 as Canadian Peptide Research Supply Demand Grows
06/10/2026
Toronto, ON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced an expanded focus on providing information and access to research peptide supplies for Canadian laboratories, academic researchers and [...]
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »
06/10/2026
Mise en ligne du document «Q3 2026 aide-mémoire » Paris, France – 6 octobre 2026 . Sanofi annonce la mise en ligne de son « Q3 2026 aide-mémoire » sur la page « Investisseurs » de sanofi.com. Résultats du troisième [...]
Press Release : Availability of the aide-mémoire for Q3 2026 results
06/10/2026
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026 . Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter [...]
Kylo Peptides Review Brings Transparency to the Research Peptide Market
06/10/2026
Review highlights testing documentation, lot-specific COAs, independent laboratory analysis, and supplier information to help researchers evaluate research peptide sources. Sheridan, Wyoming, Oct. 06, 2026 (GLOBE [...]
Bulk Peptides: Kylo Peptides Launches Bulk Research Program for High-Volume Laboratories
06/10/2026
Sheridan, Wyoming, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has introduced a research program that supplies bulk peptides to laboratories with higher-volume peptide requirements. It [...]
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
06/10/2026
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma [...]
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
06/10/2026
First clinical data for CPV-104 in patients, including interim safety, tolerability and pharmacokinetics, accepted as a late-breaking poster Expert panel to join One04 management in a virtual key opinion leader (KOL) [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation [...]
Legacy Opens Acres Homes Clinic to Expand Access to Care in a Historic Houston Community
06/10/2026
New 26,200-square-foot clinic brings coordinated, affordable care under one roof for Acres Homes families Legacy Community Health, Houston Methodist, elected officials and community leaders celebrate the grand opening [...]
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
06/10/2026
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
Baylor Genetics Selected as the Lead Sequencing Partner for Florida’s Sunshine Genetics Pilot Program Launch
05/10/2026
The company will provide comprehensive Whole Genome Sequencing for the initial launch of the first statewide genomic newborn screening program HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading [...]
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
05/10/2026
Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and [...]
Cerene® Cryotherapy Brings Free Mother-Daughter Period Education Brunch to Indianapolis Area
05/10/2026
CARMEL, Ind., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Channel Medsystems’ Cerene® Cryotherapy is bringing its Cycles & Seasons Mother-Daughter Brunch to the Indianapolis area on Saturday, October 10, offering local [...]
FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms
05/10/2026
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Click Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (marketing authorization) for Motivista, a prescription [...]
Major shareholder announcement - BlackRock, Inc.
05/10/2026
ANNOUNCEMENT NO. 318 5 October 2026 Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec that, on 29 September 2026, BlackRock, Inc. increased its [...]
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
05/10/2026
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 [...]
iCell Gene Therapeutics Announces Upcoming Conference Presentations
05/10/2026
STONY BROOK, N.Y., Oct. 05, 2026 (GLOBE NEWSWIRE) -- iCell Gene Therapeutics ("iCell Gene"), a clinical-stage biopharmaceutical company developing autologous and in vivo CAR T cell therapies for autoimmune diseases and [...]
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
05/10/2026
- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma [...]
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/10/2026
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically [...]

Pages